关键词:

子痫前期, 双调蛋白, 亲环素A, 不良妊娠结局

Abstract:

Objective　To explore the value of combined serum levels of Amphiregulin and cyclophilin A (CYPA) in predicting adverse pregnancy outcomes in preeclampsia patients. Methods　Ninety-six preeclampsia patients [aged (28.96±5.24) years, with a gestational age of (29.36±3.58) weeks and a body mass index (BMI) of (22.94±2.03) kg/m²] admitted to Northwest Women's and Children's Hospital from March 2020 to March 2023 were included. According to the pregnancy outcomes, the preeclampsia patients were divided into a normal outcome group (73 cases) and an adverse outcome group (23 cases). Another 50 healthy pregnant women during the same period were selected as a control group, aged (29.01±5.21) years, with a gestational age of (29.47±3.52) weeks and a BMI of (22.99±2.11) kg/m². Enzyme linked immunosorbent assay (ELISA) was used to detect the serum Amphiregulin and CYPA levels at 34-36 weeks of gestation in the three groups, and Spearman correlation analysis was used to analyze the correlations between serum Amphiregulin and CYPA levels and adverse pregnancy outcomes in preeclampsia patients. The receiver operating characteristic curve (ROC) was used to analyze the value of combined serum Amphiregulin and CYPA levels in predicting adverse pregnancy outcomes in preeclampsia patients. One-way analysis of variance and LSD-t test were used for statistical analysis. Results　Serum levels of Amphiregulin [(970.21±31.36) ng/L] and CYPA [(96.21±9.71) ng/L] in the adverse outcome group were higher than those in the normal outcome group [(862.25±27.25) ng/L and (79.58±7.22) ng/L] and the control group [(792.32±23.36) ng/L and (59.14±5.36) ng/L], with statistically significant differences (all P<0.05). Correlation analysis showed that serum levels of Amphiregulin and CYPA were positively correlated with adverse pregnancy outcomes in preeclampsia patients (r=0.855 and 0.673, both P<0.05). ROC analysis results showed that the sensitivity and specificity of serum Amphiregulin and CYPA levels combined to predict adverse pregnancy outcomes in preeclampsia patients were 91.3% and 84.9%, respectively, and the area under the curve was 0.920, which was higher than that of any single test. Conclusions　The serum levels of Amphiregulin and CYPA in preeclampsia patients are higher than those in normal pregnant women. The levels of the two indicators are positively correlated with adverse pregnancy outcomes. Their combined use can effectively predict adverse pregnancy outcomes in preeclampsia patients, showing high sensitivity and specificity.

Key words:

Preeclampsia, Amphiregulin, Cyclophilin A, Adverse pregnancy outcomes